Thermo Fisher

Thermo Fisher announced last week that it will buy North Carolina-based clinical research organization PPD for $17.4 billion in cash and approximately $3.5 billion in assumed debt.

In a boost to its pharma services business, the Massachusetts-based company will acquire PPD’s drug development platform, patient recruitment capabilities and laboratory services, the press release said.

The deal is one of several acquisitions for Thermo Fisher this year and, according to STAT, its…

Mentions:

The state of the hunt:

J&J’s vaccine became the first single-dose Covid-19 jab to receive EUL from the World Health Organization.
  A growing list of countries—including at least one COVAX AMC participant—suspended their rollouts of AstraZeneca’s vaccine over safety concerns.
  Monoclonal antibodies from Lilly and a separate mAb from GSK and Vir substantially cut the risk of hospitalization or death in people with mild or moderate Covid-19 at high risk of progression…

The state of the hunt:

COVAX has inked a deal for up to 40 million doses of Pfizer/BioNTech’s vaccine.
  India launched its mass vaccination campaign against Covid-19.
  China and India are both giving away vaccine doses to their neighbors.

 

Vaccines


Approved or authorized vaccines
 
China’s Sinovac jab more effective using three-week interval: A silver lining has emerged to last week’s middling news from the Butantan Institute’s…

Massachusetts-based Thermo Fisher announced last week its $877 million all-cash acquisition of Novasep’s Belgian viral vector manufacturing business, Henogen. The purchase will help Thermo Fisher “expand its capabilities for cell and gene vaccines and therapies globally,” the press release said.

Fellow CDMO Fujifilm Diosynth Biotechnologies also has new manufacturing muscle in the works. Fujifilm and its collaborator, the Massachusetts Center for Advanced Biological Innovation and…

Two companies last week extended a veritable frenzy of recent industry capacity enhancement announcements.

Massachusetts-based Thermo Fisher said it will expand its sterile drug development and commercial manufacturing facilities—including live virus, aseptic liquid and lyophilized vial filling capabilities—in North Carolina, the United Kingdom and Italy. The expansions are in addition to new facilities in Singapore and China the company already announced, the press release said.

The state of the hunt:

Pfizer/BioNTech’s vaccine won U.S. FDA Emergency Use Authorization.
  The inactivated vaccine from CNBG’s Beijing subsidiary secured UAE registration.
  Bharat Biotech and SII requested Indian authorization of their respective jabs.

 

Vaccines


Approved or authorized vaccines
 
The Pfizer/BioNTech vaccine extended its regulatory lead this week with new authorizations, including a U.S. nod.
 
The U.S.…

The state of the hunt:

Vaccine candidates from Novavax and J&J’s Janssen subsidiary entered Phase 3.
  Chinese regulators are reviewing inactivated vaccine candidates from CNBG for conditional authorization.
  Fujifilm’s flu drug Avigan (favipiravir) met its primary endpoint in a Phase 3 trial for treatment of Covid-19.

 

Vaccines

Phase 3 candidates:
 
China weighs approval of CNBG shots: State regulators are reviewing CNBG’s two…

The state of the hunt:

Serum Institute of India is reportedly pursuing up to $1 billion in private equity funding for its Covid-19 vaccine projects.
  J&J plans 60,000-participant Phase 3 trials of its Janssen subsidiary’s vaccine candidate.
  Roche will help develop and manufacture Regeneron’s REGN-COV2 antibody cocktail, more than tripling production capacity of the drug.

 

Vaccines

Phase 3 trials:
 
Brazil approved Phase 3 trials of…

Dutch diagnostics specialist Qiagen formally backed out of Thermo Fisher’s $12.5 billion takeover bid last week, announcing that the number of shares tendered failed to reach the minimum required for the deal. Qiagen’s sales rose 14% in the first half of 2020 on strong demand for its Covid-19 tests, the company said in its press release.

Qiagen also reported progress toward the launch of QuantiFERON-TB Access, a tuberculosis blood test intended for low-resource settings.


The state of the hunt: 

Novavax became the biggest recipient of CEPI funds for Covid-19 this week, with a new $384 million award for its recombinant protein vaccine candidate. CureVac’s mRNA vaccine candidate induced high levels of virus-neutralizing titers at a low dose in preclinical studies. Gilead announced voluntary royalty-free licenses for remdesivir with five generic drug manufacturers, and more may be in the works.
 

 

Vaccines

Our Covid-19…